The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Biologic study of the effects of lapatinib in PI3K/akt- and ras/raf/MAK-signaling pathways in HER2-positive ductal breast carcinoma in situ (DCIS).
L. GarcĂ­a-Estevez
No relevant relationships to disclose